Research Unit

Mary Chiles General Hospital

COVID-19

Livzon Pharmaceutical Group

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

A Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III

Mary Chiles General Hospital | Research Unit

Site insights

Work at this site?

Active trials

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III (COVID-19)

Trial sponsors